Evaluation of cfDNA as a Marker of Response in Rectal Cancer

Cancer of Rectum Clinical Trial

Official title:

Evaluation of cfDNA as a Marker of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04319354
• Other study ID #: 85/19/56C
• Status: Completed
• Phase: N/A
• Start date: November 18, 2019
• Est. completion date: December 30, 2021

Study information

• Verified date: May 2023
• Source: Hospital Pedro Hispano
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A pathological complete response (pCR) after surgery occurs in approximately 20% of rectal cancer patients submitted to neoadjuvant chemotherapy, with apparent survival benefit. This group could, potentially, be spared the morbidity of surgery.

The diversified response to neoadjuvant chemotherapy (nCRT) amongst tumors suggests a complex relationship between tumor biology and response possibly due to a number of genetic or molecular pathways that might regulate chemoradiosensitivity.

Accumulating evidence indicated that circulating cell-free nucleic acids can be a promising biomarker of response, in liquid biopsy, for rectal cancer. The concentration of baseline plasma cell-free DNA (cfDNA) appears significantly higher in responders compared to non-responders.

The objective of this study is to investigate the potential role of cfDNA as a marker of pCR (or partial response) to nCRT as well as a marker of outcomes (overall survival and disease-free survival).

The investigators are conducting a prospective, observational, cohort, non-randomized study of consecutive patients with locally advanced rectal cancer submitted to nCRT, followed by surgical excision 6-12 weeks later. Patients are assigned to groups according to their pathological response to nCRT. A total of 20 patients with complete pathological response, 50 partial response and 50 non-responders will be selected over a year and followed for another year. Participants will be observed and examined during the entire course of treatment and the follow-up period.

Serial analysis of cfDNA through liquid biopsies will be performed in consecutive patients at specific time points (pre-nCRT, post-nCRT and postoperative week 1), incorporating analysis of concentration, dimension of DNA fragments, % of mutation frequency (CIN, APC, p53, MSI, KRAS, BRAF, EGFR, cKIT) and next-generation sequencing of tumour biopsy and surgical specimens.

This study will serve as the feasibility of a larger, comparative study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 30, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients aged over 18 years old, ECOG 0-2

2. High-risk patients with biopsy proven rectal adenocarcinoma who will undergo long-course chemoradiotherapy and who are potentially eligible for curative surgery

3. Patients who can fully understand the content of the informed consent form and sign it upon their own opinion

4. Patients who can coordinate with the researchers to undergo the long-term post-treatment rechecks and follow-up

Exclusion Criteria:

1. Patient has any underlying or current medical condition, which would interfere with the evaluation of the patient (e.g., end-stage liver disease, pulmonary hypertension, systemic lupus erythematosus etc.).

2. Patient has severe mental illness.

3. Patient has any other conditions, which would interfere with the evaluation of the subject.

Related Conditions & MeSH terms

• Cancer of Rectum
• Rectal Neoplasms

Intervention

Diagnostic Test:
• Analysis of cfDNA
Analysis of cfDNA through liquid biopsy

Locations

Country	Name	City	State
Portugal	Hospital Pedro Hispano	Matosinhos	Porto

Sponsors (5)

Lead Sponsor	Collaborator
Hospital Pedro Hispano	Diogo Melo Pinto, MD, Hospital Pedro Hispano, Isabel Prieto, PhD, Hospital La Paz, Madrid, Silvestre Carneiro, PhD, Centro Hospitalar de São João, Telma Fonseca, MD, Centro Hospitalar de São João

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ryan tumor regression grade system (number of patients with complete/partial/no response)	Tumour pathological response, on surgical specimen, to neoadjuvant chemoradiotherapy	Through study completion, an average of 1 year
Secondary	Number of participants with 1 and 2-year disease free recurrence		1 and 2 years